[b]I hate to advocate drugs, alcohol, violence, or insanity to anyone, but they've always worked for me.[/b]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
eel at the bottom of the Mariana Trench
In the meanwhile you miss the best bull market in history
Me? An Elite bag holder and proud of it. Accumulating more when I get the chance.
Holding bags of Elite shares now.... soon to be bags of $$$$$$$$.
Correct. Norco is not on the monster list. It is a supplemental to a growing list of revenue generating drugs like Percocet, Methadone, although Percocet and Norco will make way more money than a methadone IMO.
Once Norco gets approval then I think it gets bundled with Percocet. Could be wrong though. There is a plan going forward, we just do not know what that plan is.
Percocet and Norco should do well for small revenues. One, definitely both should make Elite CFP.
Methadone isn't much but adds to total revenue no matter how one slices it.
Elite WILL have a formidable drug portfolio going forward. A buyout portfolio.
Lot of volume today. What in the world is driving it?
Geee Wally what is it?
Gosh, I dunno Beave……….
Yes. Not if.... it is when.
3.0% equals $48 million. Even the most conservative take on revenue will be a tremendous take. And it only grows in market share from there.
This is SunGen's proprietary platform which will more than likey make the Elite/SunGen line more competitive in price than the competition.
It will be fun to watch, that's for sure.
He can't. Fact.
Pfizer's Troxyca was approved by the FDA and then "discontinued" in order to block the competition from putting out a better version of a flawed formulation. Elite has that better Troxyca ER at the ready, but alas no comparator.....
Looking at a few things tonight I stumbled onto this excerpt from an article I read.
Last year, Celgene paid $280 million to settle a whistle-blower lawsuit claiming it had inappropriately promoted Revlimid and Thalomid to treat a range of cancers beyond what the Food and Drug Administration had approved. Several generic drug companies have sued the company claiming that Celgene denied them access to drug samples needed to make cheaper copies.
Seems the FDA has some clean up work in aisle 1, the denying access to comparators aisle.
Tee minus sometime in the future.
A. Fatmi, Ph.D experience in this area as well.....
supply chain management, operations excellence and business development.
Could be you may be right. My thoughts on this new board member go beyond
his experience in the buyout/acquisition area. No doubt he is there for that reason. He also has experience in other areas, and I think it is that which Elite will use for now. He is more than a one trick board member.
Insiders are holding tight. They know what they have in Elite. Elite's
product portfolio will make them a unique buyout opportunity in my not so humble opinion.
If they ever get SequestOx through, then couple that with an ER ADF using their two bead PIP, the ADF platform alone will be enough to jack the buyout price well north of $2-4/share. Add the Elite/SunGen products using SunGen's platform and what more need I say?
Oh, they will try to get Elite for pennies...… good luck with that though.
Again, all in my not so humble opinion.
ANDA NDA with the FDA.
I think Elite is done with Epic now PuraCap. Epic kind of sold Elite down the river when they agreed to take those site transfers from Elite.
Little did NH know Epic was going to be bought out. I don't think he would have made that type of contract with Epic had he known Epic was soon to be PuraCap.
Elite will put a PR out today in 4 hours 11 seconds about having met with the FDA. NOT~!
SequestOx is about renegotiating with a company who did nothing with generics Elite gave them. Epic sat on them. One does not negotiate with
companies who do not fulfill their obligations. Sorry Ama but you are WAY off on that one.
The renegotiation of the Epic SequestOx contract is what is holding up the press release.
As of today, all 13 products are now back in Elite's hands.
It is hard to be a step ahead of a fixed game. Until companies like Pfizer and others are forced to market or make available their approved formulations instead of stalling it will be the same old same old.
This FDA so far has been all talk. Gottlieb has done nothing to improve anything. Administration hand picked him for a reason NASDAQ.
What will force pharmaceutical companies to put their flawed products out once approved are stiff and heavy fines if they do nothing but stall. Money talks that way too.
Meanwhile Gottlieb does what his boss tells him to do and nothing more.
Ease restrictions on companies that want to pay for play. All quite apparent in what is really going on here.
As well as at Purdue they are obviously overlooking the abuse of Purdue's primary formulation.... OxyContin.
They must be overlooking all kinds of issues.....
...is that the first time we heard "near the end"?
Not so fast.
Whether Hamburg, Gottlieb or anyone else, nothing will change.
When Elite’s second gen Immediate release comes out it will make all IR opioids obsolete.
The New Unique IR AF platform is 90% cheaper.
The only thing Elite got validated from the FDA on SequestOx was the CRL.
I belive a small pharma company like Elite has done a great job in last couple years and big pharma seems willing to knock her down through lobbying etc as they know Elite is a sleeping monster under the radar at OTC market.
Funny thing is that NH never said Elite would or would not.
Norco time.
Purdue (Sackler family) has plenty of money welding power Gman.
Not until Purdue gets hit with a very heavy law suit they have to pay and cannot go through the usual means of payment where the company does not take the brunt..... otherwise it is business as usual at Purdue. Scott Gottlieb has no power to do anything. Basically a puppet in this administration.
Money talks alright, and the FDA cannot do a thing so long as someone else is pulling the strings. Purdue is being somewhat protected in my opinion.
Make money addicting people to an opioid formulation that can easily be ABUSED, then treat those you addicted with a patented treatment formulation. All while being protected by the current administration because the Sackler bunch has that type of clout by means of money and power.
Meanwhile companies like Elite are stalled by whatever means possible. There is one problem with that ploy though.... Elite will get a patent for their new IR formulation. Purdue and this administration cannot hold out forever. Don't expect Gottlieb will be head of the FDA if this administration gets voted out. The worm will turn.... and Scotty won't be there to see it through. Just my opinion. The opioid crisis will continue to worsen because there is no one or body to stop it so long as big money is made and someone gets paid.
It is totally sick. Money over people. Just sick.
So Elite hired guys to manipulate ELTP up, eh?
Don't think so.
Avridi was smoked by the AdCom 23-1
One can only hope,
SequestOx developed with close collaboration with the FDA.
Elite manipulated up to $0.97 and shorted all the way back down. I agree, manipulators made money going up and have made money going back down.
Good stuff on NPR this morning concerning the opioid crisis in Philadelphia area. Basically Purdue seen as one of the main pharmaceutical players. At one time Purdue had 5000 doctors and nurses hawking their OyxContin as the safest most non-addictive opioid for pain. Even claims of 12 hour relief, which have been proven FALSE.
Really wished I could have called in to that segment to tell listeners about the latest patent for a treatment to opioid addiction by Purdue. Not sure if the authors of that book knew about that, but they did know about Giuliani representing Purdue in several lawsuits. From what I understood through legal maneuvers Purdue didn't really pay much of the fine as the company Purdue. They weaseled their way out of it.
The roots of the overdose crisis
https://whyy.org/episodes/the-roots-of-the-overdose-crisis/
Very good listen.
In the world of injectables there are often opportunities that present themselves. I'm pretty sure this applies to solid dosage as well.
In any case, your viewpoint is very much appreciated Drugdoctor. You have a perspective few others have. In essence you have your finger on the pulse of what is really going on.
Healthcare professionals only get one side of it as do others who work in pharmaceuticals. You, on the other hand, see the where, what, and who.
Thanks for that informative post.
JJ
Please post facts via data that says these markets are flooded and saturated.
FLOODED saturated markets are hard to get into.
2018 is still young. 2019 is yet to come.
Norco coming. Soon? Maybe, maybe not. Should be soon. Patience is a virtue.
Well Jour, we will just have to be patient and wait for those fake news Elite/SunGen ANDAs to get approval.
Pilot study not only included SequestOx but also included the ADF without naltrexone that will be cheaper to make, no doubt.
Don't think Elite is in oncology. You may want to go to PMCB for that sort of thing.
Parkinson could be very possible along with blood pressure though.
Epic's bad. If Elite is smart they will steer away from dealing with that company from now on. PuraCap can pack sand.
Nonsense.
Percocet and Norco coupled together as a bundled launch. That will make Elite CFP.
SunGen ANDAs two of which have tremendous markets to exploit.
Just SunGen ANDAs alone will give Elite a beyond dollar land price tag.
Isradipine and SequestOx are on the waiting list.
Isradipine is a question mark. Nice thing is that Elite has it out on the market.
Not so much a question mark with SequestOx now that they have reformulated. If the patent is granted to Elite for the reformulation it could carry into 2030.
My opinion, SequestOx is very much underestimated in market value.
It alone could swell the share price of Elite and a buyout price.
We will see. I stand by my prediction though. Things will begin to happen sooner than later.
Better to treat the symptoms rather than the cause.